Overview

• House Oversight Committee criticizes PBMs for steering patients toward higher-priced medications.
• Executives from major PBMs defend their role, blaming drug manufacturers for high costs.
• New bipartisan bill aims to increase transparency and reform PBM practices.
• Report alleges PBMs are moving operations overseas to avoid regulatory scrutiny.
• FTC plans to sue major PBMs over their business practices.